Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Proposed issue of securities – RAD

Tuesday, June 10, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company also received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3. This marks a significant advancement in their clinical programs.
Price reaction · baseline $4.975 (2025-06-10T17:52:00.000Z) · hit during market hours · 5 other RADX headline(s) in the window, move may be shared
day 0 close · peak
-0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has received IND approval from the US FDA.
  • The company is initiating a Phase I therapeutic clinical study.
  • Positive clinical updates have been reported across four programs.

Full Press Release Details

• Announcements
• Appendix 3B
• June 10, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• July 3, 2024
• Announcements
• June 9, 2022
• Announcements
• February 6, 2024
• Announcements
• March 4, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the purpose of the Phase 1/2a study?

The Phase 1/2a study aims to evaluate BetaBart (RV-01) targeting B7H3.

Who was appointed to the scientific advisory board?

Dr. Oliver Sartor was appointed to the Radiopharm Scientific Advisory Board.

When did Radiopharm announce the first patient dosing?

Radiopharm announced the first patient dosing on October 20, 2025.

What recent approval did Radiopharm receive?

Radiopharm received IND approval from the US FDA for their study.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA approval B7H3
Last updated: Jun 10, 2025